The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Becton, Dickinson and Company’s (BD) new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV).

Designed for use on the BD MAX molecular diagnostic system, the test uses a single nasal or nasopharyngeal swab sample to detect and differentiate whether a patient has Covid-19, the flu, RSV or a combination of the three.

The Respiratory Viral Panel for BD MAX System is an RT-PCR assay, which identifies and differentiates the nucleic acid of SARS-CoV-2, flu A, flu B and RSV within two hours for the first result.

Designed to help combat illness in the current and future respiratory virus seasons, the test is claimed to enable clinicians to rapidly implement the right treatment plan.

Furthermore, the co-testing process will help enhance testing capacity as well as speed time to diagnosis during the busy flu/RSV season, stated BD.

BD molecular diagnostics vice-president Nikos Pavlidis said: “While fears of a ‘tripledemic’ this respiratory season have largely diminished, accurately differentiating influenza and RSV from Covid-19 and providing appropriate treatment remains a challenge for our customers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This diagnostic test provides the ability to identify multiple pathogens using a single sample and can quickly pinpoint the causative virus or viruses and enable clinicians to administer appropriate treatment early in the course of infection.”

The company secured the CE mark for the BD Respiratory Viral Panel assay for BD MAX System last May.

BD also introduced the new third-generation BD Kiestra Total Lab Automation System for microbiology laboratories last month.